{"id":381056,"date":"2020-11-13T15:07:32","date_gmt":"2020-11-13T20:07:32","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=381056"},"modified":"2020-11-13T15:07:32","modified_gmt":"2020-11-13T20:07:32","slug":"shareholder-alert-weisslaw-llp-investigates-urovant-sciences-ltd","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-weisslaw-llp-investigates-urovant-sciences-ltd\/","title":{"rendered":"SHAREHOLDER ALERT: WeissLaw LLP Investigates Urovant Sciences Ltd."},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n NEW YORK<\/span>, Nov. 13, 2020<\/span> \/PRNewswire\/ — WeissLaw LLP<\/a>\u00a0is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Urovant Sciences Ltd. (“UROV” or the “Company”) (NASDAQ: UROV) in connection with the proposed interested-party acquisition of the Company by Sumitovant Biopharma Ltd. (“Sumitovant”), UROV’s majority shareholder that currently owns 72% of the Company’s outstanding common shares. Under the terms of the acquisition agreement, the Company’s shareholders will receive only $16.25<\/span> in cash for each share of UROV common stock that they own. <\/p>\n

\n

\n
\n \"WeissLaw
\n <\/a>\n <\/p>\n<\/p><\/div>\n

\n
\n If you own UROV shares and wish to discuss this investigation or have any questions concerning this notice or your rights or interests, visit our website:<\/u>
\n <\/b>\n <\/p>\n

\n
\n https:\/\/www.weisslawllp.com\/urov\/<\/a>
\n <\/b>\n <\/p>\n

\n
\n Or please contact:
<\/u>
\n <\/b>
\n
\n Joshua Rubin, Esq.<\/span>
\n
\n <\/b>WeissLaw LLP
1500 Broadway, 16th<\/sup> Floor
New York<\/span>, NY\u00a0 10036
(212)\u00a0682-3025
<\/b>(888) 593-4771
stockinfo@weisslawllp.com<\/a><\/b><\/p>\n

WeissLaw is investigating whether (i) the special committee of UROV’s board was truly independent and acted to maximize shareholder value in agreeing to the proposed transaction, (ii) the $16.25<\/span> per share merger consideration adequately compensates UROV’s minority shareholders, (iii) the special committee was fully informed as to the valuation of the proposed acquisition of the Company, and (iv) all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed.\u00a0These issues are of particular concern given the influence and control Sumitovant wields over UROV by virtue of its ownership of a majority of the Company’s outstanding shares. Moreover, the per-share merger consideration is significantly lower than an analyst price target of $28.00<\/span>, suggesting the special committee may have agreed to an undervalued deal at the behest of Sumitovant.<\/p>\n

WeissLaw LLP has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties.\u00a0We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases.\u00a0If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at stockinfo@weisslawllp.com<\/a><\/b><\/p>\n

<\/div>\n

\n \"Cision\" View original content to download multimedia:http:\/\/www.prnewswire.com\/news-releases\/shareholder-alert-weisslaw-llp-investigates-urovant-sciences-ltd-301172926.html<\/a><\/p>\n

SOURCE WeissLaw LLP<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire NEW YORK, Nov. 13, 2020 \/PRNewswire\/ — WeissLaw LLP\u00a0is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Urovant Sciences Ltd. (“UROV” or the “Company”) (NASDAQ: UROV) in connection with the proposed interested-party acquisition of the Company by Sumitovant Biopharma Ltd. (“Sumitovant”), UROV’s majority shareholder that currently owns 72% of the Company’s outstanding common shares. Under the terms of the acquisition agreement, the Company’s shareholders will receive only $16.25 in cash for each share of UROV common stock that they own. If you own UROV shares and wish to discuss this investigation or have any questions concerning this notice or your rights or interests, visit our website: https:\/\/www.weisslawllp.com\/urov\/ Or please … <\/p>\n

Continue reading “SHAREHOLDER ALERT: WeissLaw LLP Investigates Urovant Sciences Ltd.”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-381056","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nSHAREHOLDER ALERT: WeissLaw LLP Investigates Urovant Sciences Ltd. - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-weisslaw-llp-investigates-urovant-sciences-ltd\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SHAREHOLDER ALERT: WeissLaw LLP Investigates Urovant Sciences Ltd. - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire NEW YORK, Nov. 13, 2020 \/PRNewswire\/ — WeissLaw LLP\u00a0is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Urovant Sciences Ltd. (“UROV” or the “Company”) (NASDAQ: UROV) in connection with the proposed interested-party acquisition of the Company by Sumitovant Biopharma Ltd. (“Sumitovant”), UROV’s majority shareholder that currently owns 72% of the Company’s outstanding common shares. Under the terms of the acquisition agreement, the Company’s shareholders will receive only $16.25 in cash for each share of UROV common stock that they own. If you own UROV shares and wish to discuss this investigation or have any questions concerning this notice or your rights or interests, visit our website: https:\/\/www.weisslawllp.com\/urov\/ Or please … Continue reading "SHAREHOLDER ALERT: WeissLaw LLP Investigates Urovant Sciences Ltd."\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-weisslaw-llp-investigates-urovant-sciences-ltd\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-13T20:07:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/743985\/WeissLaw_Logo_Stacked_LowerCase_color_2_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-weisslaw-llp-investigates-urovant-sciences-ltd\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-weisslaw-llp-investigates-urovant-sciences-ltd\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"SHAREHOLDER ALERT: WeissLaw LLP Investigates Urovant Sciences Ltd.\",\"datePublished\":\"2020-11-13T20:07:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-weisslaw-llp-investigates-urovant-sciences-ltd\\\/\"},\"wordCount\":381,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-weisslaw-llp-investigates-urovant-sciences-ltd\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/743985\\\/WeissLaw_Logo_Stacked_LowerCase_color_2_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-weisslaw-llp-investigates-urovant-sciences-ltd\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-weisslaw-llp-investigates-urovant-sciences-ltd\\\/\",\"name\":\"SHAREHOLDER ALERT: WeissLaw LLP Investigates Urovant Sciences Ltd. - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-weisslaw-llp-investigates-urovant-sciences-ltd\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-weisslaw-llp-investigates-urovant-sciences-ltd\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/743985\\\/WeissLaw_Logo_Stacked_LowerCase_color_2_Logo.jpg\",\"datePublished\":\"2020-11-13T20:07:32+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-weisslaw-llp-investigates-urovant-sciences-ltd\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-weisslaw-llp-investigates-urovant-sciences-ltd\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-weisslaw-llp-investigates-urovant-sciences-ltd\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/743985\\\/WeissLaw_Logo_Stacked_LowerCase_color_2_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/743985\\\/WeissLaw_Logo_Stacked_LowerCase_color_2_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-weisslaw-llp-investigates-urovant-sciences-ltd\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SHAREHOLDER ALERT: WeissLaw LLP Investigates Urovant Sciences Ltd.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"SHAREHOLDER ALERT: WeissLaw LLP Investigates Urovant Sciences Ltd. - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-weisslaw-llp-investigates-urovant-sciences-ltd\/","og_locale":"en_US","og_type":"article","og_title":"SHAREHOLDER ALERT: WeissLaw LLP Investigates Urovant Sciences Ltd. - Market Newsdesk","og_description":"PR Newswire NEW YORK, Nov. 13, 2020 \/PRNewswire\/ — WeissLaw LLP\u00a0is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Urovant Sciences Ltd. (“UROV” or the “Company”) (NASDAQ: UROV) in connection with the proposed interested-party acquisition of the Company by Sumitovant Biopharma Ltd. (“Sumitovant”), UROV’s majority shareholder that currently owns 72% of the Company’s outstanding common shares. Under the terms of the acquisition agreement, the Company’s shareholders will receive only $16.25 in cash for each share of UROV common stock that they own. If you own UROV shares and wish to discuss this investigation or have any questions concerning this notice or your rights or interests, visit our website: https:\/\/www.weisslawllp.com\/urov\/ Or please … Continue reading \"SHAREHOLDER ALERT: WeissLaw LLP Investigates Urovant Sciences Ltd.\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-weisslaw-llp-investigates-urovant-sciences-ltd\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-13T20:07:32+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/743985\/WeissLaw_Logo_Stacked_LowerCase_color_2_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-weisslaw-llp-investigates-urovant-sciences-ltd\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-weisslaw-llp-investigates-urovant-sciences-ltd\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"SHAREHOLDER ALERT: WeissLaw LLP Investigates Urovant Sciences Ltd.","datePublished":"2020-11-13T20:07:32+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-weisslaw-llp-investigates-urovant-sciences-ltd\/"},"wordCount":381,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-weisslaw-llp-investigates-urovant-sciences-ltd\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/743985\/WeissLaw_Logo_Stacked_LowerCase_color_2_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-weisslaw-llp-investigates-urovant-sciences-ltd\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-weisslaw-llp-investigates-urovant-sciences-ltd\/","name":"SHAREHOLDER ALERT: WeissLaw LLP Investigates Urovant Sciences Ltd. - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-weisslaw-llp-investigates-urovant-sciences-ltd\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-weisslaw-llp-investigates-urovant-sciences-ltd\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/743985\/WeissLaw_Logo_Stacked_LowerCase_color_2_Logo.jpg","datePublished":"2020-11-13T20:07:32+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-weisslaw-llp-investigates-urovant-sciences-ltd\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-weisslaw-llp-investigates-urovant-sciences-ltd\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-weisslaw-llp-investigates-urovant-sciences-ltd\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/743985\/WeissLaw_Logo_Stacked_LowerCase_color_2_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/743985\/WeissLaw_Logo_Stacked_LowerCase_color_2_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-weisslaw-llp-investigates-urovant-sciences-ltd\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"SHAREHOLDER ALERT: WeissLaw LLP Investigates Urovant Sciences Ltd."}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/381056","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=381056"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/381056\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=381056"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=381056"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=381056"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}